Elicio Therapeutics
ELTX on Nasdaq. Market value $50m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 48 funds in all.
Largest holders overall
- Knoll Capital Management$5mAdded
- BlackRock$3mAdded
- Vanguard Capital Management$2mAdded
- Geode Capital Management$1mAdded
- State Street$701,532Added
- Northern Trust$508,933Added
- Ikarian Capital$391,000New
- Vanguard Portfolio Management$347,619New
- Vanguard Fiduciary Trust$344,322Added
- Alliancebernstein L.P.$317,805New
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- GKCC, LLCat least 48.0%−0.1 pts(filed with 1 related holder)Since 3 June 2025
What they said
Item 4 is hereby amended and supplemented as follows: The response to Item 3 of this Schedule 13D is incorporated by reference herein.
Read the filing - Moti Investments LLCPassive investor6.1%Since 1 July 2026
- Knoll Capital Management, LLCPassive investorat least 5.3%+0.1 pts(filed with 2 related holders)Since 1 July 2026
- Actyus Private Equity SGIIC, S.A.Passive investorSold down below 5%Since 30 September 2025
| Holder | Stake | Since | |
|---|---|---|---|
GKCC, LLC | at least 48.0%−0.1 pts (filed with 1 related holder) | 3 June 2025 | What they saidItem 4 is hereby amended and supplemented as follows: The response to Item 3 of this Schedule 13D is incorporated by reference herein. Read the filing |
Moti Investments LLC Passive investor | 6.1% | 1 July 2026 | |
Knoll Capital Management, LLC Passive investor | at least 5.3%+0.1 pts (filed with 2 related holders) | 1 July 2026 | |
Actyus Private Equity SGIIC, S.A. Passive investor | Sold down below 5% | 30 September 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought or sold on the open market in the last 12 months.
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Elicio Therapeutics’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 13 Aug 2026 and 8 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“The Company’s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about the Company’s ability to continue as a going concern.”
Show the full paragraph
As of June 30, 2026, the Company had $ 23.5 million in cash and cash equivalents. The Company’s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development. The Company plans to address this condition through the sale of Company common stock or other securities in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all. If the Company is unable to obtain additional capital when and as needed to continue as a going concern, it may need to further reduce or scale back its operations and/or liquidate its assets, and the values it receives for its assets in liquidation or dissolution could be significantly lower than the values reflected in its financial statements.
From the 10-Q filed 13 August 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.